tract
tissu
blood
human
anim
case
human
plasmaderiv
product
still
remain
therapeut
option
eg
intraven
immunoglobulin
major
benefit
recombin
protein
serv
platform
develop
advanc
product
engin
improv
therapeut
profil
enhanc
safeti
lower
immunogen
increas
halflif
improv
bioavail
number
recombin
therapeut
protein
includ
recombin
human
insulin
produc
microbi
express
system
establish
use
bacteria
yeast
howev
product
larger
complex
protein
often
requir
extens
posttransl
modif
particularli
glycosyl
microbi
system
perform
modif
necessari
proper
protein
structur
function
instead
mammalian
express
system
tradit
approach
largescal
manufactur
therapeut
protein
requir
critic
posttransl
modif
addit
advantag
mammalian
cell
system
recombin
protein
secret
media
natur
form
e
coliexpress
protein
hand
mostli
accumul
highli
denatur
form
within
cell
inclus
bodi
requir
renatur
later
manufactur
process
recombin
protein
therapeut
produc
mammalian
cell
primarili
chines
hamster
ovari
cho
cell
cho
cell
mani
characterist
made
wide
use
mammalian
host
system
addit
eas
manipul
characterist
prefer
largescal
product
protein
protein
produc
cho
cell
proven
safeti
profil
human
protein
also
glycosyl
pattern
similar
human
protein
advanc
modul
glycosyl
pattern
yeast
strain
eg
p
pastori
may
lead
altern
nonmammalian
cell
system
futur
current
mammalian
cell
remain
primari
vehicl
largescal
product
recombin
therapeut
glycoprotein
hemophilia
xlink
coagul
disord
result
mutat
coagul
factor
viii
fviii
gene
patient
sever
hemophilia
reli
exogen
factor
viii
therapi
prevent
counter
debilit
potenti
lifethreaten
consequ
prolong
bleed
driven
primarili
need
improv
safeti
factor
viii
replac
therapi
evolv
initi
use
whole
blood
citrat
plasma
cryoprecipit
first
step
evolut
switch
plasmaderiv
purifi
fviii
concentr
follow
recombin
fviii
concentr
start
final
animaland
humanplasma
free
recombin
fviii
start
fig
absenc
cure
hemophilia
develop
plasmafre
pf
recombin
fviii
elimin
risk
bloodborn
infect
lifelong
therapi
addit
biopharmaceut
manufactur
deriv
varieti
human
anim
sourc
includ
blood
milk
bone
hide
tendon
hair
skin
pancrea
fig
main
threat
howev
associ
use
blood
serumderiv
protein
tradit
cell
grown
serumbas
medium
rich
growth
factor
supplement
without
therapeut
protein
could
produc
commerci
scale
serum
howev
present
mani
challeng
biopharmaceut
manufactur
viral
outbreak
mad
cow
diseas
epidem
highlight
risk
pathogen
transmiss
serum
concern
aros
safeti
recombin
protein
produc
cell
grown
figur
evolut
safeti
measur
factor
viii
replac
therapi
box
arrow
highlight
pathogen
transmit
hemophilia
patient
bloodderiv
addit
box
arrow
repres
process
step
enabl
higher
puriti
product
develop
lead
plasmafre
recombin
factor
viii
nat
nucleic
acid
amplif
test
presenc
ingredi
sourc
human
anim
addit
recombin
protein
product
process
encumb
requir
serum
due
serum
high
protein
content
variabl
inclus
serum
potenti
increas
immunogen
certain
product
review
discuss
driver
behind
develop
plasmafre
process
respons
regulatori
physician
organ
advanc
enabl
elimin
serumderiv
addit
manufactur
recombin
therapeut
protein
serum
compon
routin
use
cell
cultur
media
support
growth
cell
line
serum
compon
albumin
gelatin
commonli
use
stabil
formul
recombin
therapeut
protein
fig
past
sever
decad
howev
brought
light
seriou
risk
associ
use
anim
human
compon
manufactur
therapeut
notabl
transmiss
infecti
agent
fig
risk
amplifi
human
andor
animalderiv
materi
use
multipl
step
manufactur
process
treatment
modal
requir
repeat
administr
product
mani
emerg
bloodborn
infecti
agent
character
longlast
silent
carrier
state
pathogen
present
circul
without
caus
obviou
notic
symptom
blood
plasma
collect
asymptomat
latent
phase
highli
infecti
exemplifi
human
immunodefici
viru
hiv
infect
nearli
million
peopl
worldwid
estim
million
peopl
current
infect
hiv
yet
vast
major
individu
unawar
hiv
statu
http
wwwunaidsorgenknowledgecentrehiv
coronaviru
respons
sever
acut
respiratori
syndrom
sar
anoth
exampl
emerg
human
pathogen
result
zoonot
transmiss
unlik
hiv
coronaviru
caus
sever
short
epidem
follow
adapt
new
human
host
mani
epidemiologist
predict
similar
type
outbreak
emerg
virus
futur
greatest
threat
biopharmaceut
manufactur
nonlipid
envelop
nle
virus
circovirus
circovirus
includ
torquetenoviru
ttv
torquetenominiviru
ttmv
smallest
known
mammalian
nle
virus
elimin
nanofiltr
histor
risk
pathogen
transmiss
particular
concern
manufactur
bloodderiv
coagul
factor
earli
plasmaderiv
factorreplac
product
use
treat
hemophilia
found
contamin
hiv
hepat
b
c
virus
fig
us
patient
hemophilia
infect
hiv
infect
hcv
consequ
life
expect
patient
hemophilia
us
decreas
year
year
subsequ
new
donor
screen
method
well
virusinactiv
remov
measur
adopt
method
improv
safeti
plasmaderiv
plasmacontain
product
new
case
hiv
hbv
hcv
transmiss
plasma
recombin
therapi
report
us
sinc
wwwhemophiliaorg
howev
solventdeterg
common
viru
inactiv
techniqu
use
prepar
plasmaderiv
product
mainli
effect
lipidenvelop
virus
hiv
hbv
hcv
htlv
human
tcell
lymphotrop
viru
wnv
west
nile
viru
nle
virus
parvovirus
enterovirus
circovirus
resist
inactiv
via
solventdeterg
treatment
degre
heat
radiat
well
parvoviru
two
genotyp
parvoviru
found
contamin
plasmaderiv
factor
viii
concentr
thu
risk
viral
infect
remain
plasmaderiv
plasmacontain
recombin
fviii
product
use
clone
fviii
gene
led
develop
first
recombin
fviii
therapi
recombin
baxter
initi
licens
us
recombin
fviii
product
classifi
three
gener
defin
masac
medic
scientif
advisori
council
nation
hemophilia
foundat
base
degre
elimin
plasma
albumin
product
andor
formul
step
outlin
tabl
masac
first
gener
product
use
plasma
andor
albumin
cell
cultur
process
final
formul
step
nd
gener
product
use
serum
protein
cell
cultur
process
earli
recombin
product
effect
reduc
risk
pathogen
transmiss
presenc
serum
compon
still
concern
inde
one
first
gener
recombin
fviii
product
contain
human
serum
albumin
kogen
bayer
suggest
sourc
transmiss
moreov
presenc
human
anim
protein
therapeut
product
potenti
put
patient
risk
contract
novel
infect
includ
caus
notyet
detect
pathogen
concern
prompt
masac
issu
recommend
manufactur
recombin
product
strongli
encourag
avoid
use
human
anim
protein
manufactur
product
complet
remov
plasma
protein
cell
cultur
final
formul
process
could
risk
infecti
diseas
transmiss
recombin
product
total
elimin
plasmafre
recombin
protein
classifi
third
gener
product
first
recombin
fviii
product
fit
criteria
advat
baxter
becam
avail
us
eu
advat
produc
cho
cell
adapt
grow
medium
free
humanand
animalderiv
addit
specif
serumand
proteinfre
synthet
minim
medium
use
produc
advat
contain
ultrafilt
soy
bean
peptid
averag
molecular
weight
dalton
along
sugar
salt
compon
ad
nourish
cho
cell
fviii
purifi
seri
chromatographi
step
includ
immunoaffin
chromatographi
process
util
monoclon
antibodi
produc
hybridoma
cell
grown
gener
plasmafre
environ
advat
stabil
trehalos
therefor
sinc
advat
never
expos
plasma
risk
transmit
known
emerg
bloodborn
pathogen
elimin
current
manufactur
process
address
diseas
threat
endang
blood
suppli
past
other
donat
plasma
routin
screen
exampl
human
herpesviru
caus
agent
kaposi
sarcoma
shown
transmit
blood
blood
product
although
lipid
membran
envelop
virus
gener
render
suscept
inactiv
combin
solvent
deterg
transmiss
lipidenvelop
wnv
via
blood
transfus
http
wwwcdcgovmmwrpreviewmmwrhtml
still
rais
new
concern
safeti
blood
suppli
therefor
due
fact
solventdeterg
nanofiltr
techniqu
effici
pathogen
plasma
compon
need
complet
remov
manufactur
process
order
elimin
risk
pathogen
transmiss
blood
compon
prion
selfrepl
infecti
protein
caus
current
untreat
fatal
neurodegen
disord
detect
new
strain
prion
human
prompt
signific
chang
regulatori
requir
biopharmaceut
manufactur
public
health
polici
consumpt
meat
contamin
bovin
spongiform
encephalopathi
bse
caus
outbreak
variant
creutzfeldtjacob
diseas
vcjd
unit
kingdom
septemb
primari
case
vcjd
report
countri
includ
uk
us
franc
http
wwwcjdedacukvcjdworld
htm
unlik
case
classic
cjd
prion
caus
vcjd
found
higher
concentr
lymphoid
tissu
therefor
present
potenti
threat
transmiss
blood
plasma
inde
four
transfusiontransmit
case
vcjd
report
http
wwwhpaorguk
infectionstopicsazcjdvcjdblooddonorshtm
confirm
case
patient
receiv
red
blood
cell
product
donor
later
develop
vcjd
latest
case
report
uk
health
protect
agenc
describ
individu
diagnos
vcjd
nine
year
receiv
blood
transfus
asympto
biotechnol
j
wwwbiotechnologyjournalcom
matic
infect
donor
none
four
case
transfusiontransmit
vcjd
transmiss
associ
plasmaderiv
factor
concentr
case
vcjd
transmiss
via
blood
transfus
report
us
howev
potenti
vcjd
transmiss
via
plasma
product
exclud
yet
nine
year
studi
sheep
demonstr
two
differ
tse
agent
bse
scrapi
unexpectedli
high
rate
transmiss
blood
transfus
rel
short
consist
incub
period
experi
suggest
infect
titer
blood
quit
high
blood
transfus
repres
effici
rout
transmiss
prion
ad
concern
prion
highli
resist
physicalchem
inactiv
virusremov
method
specif
target
addit
way
detect
prion
plasma
donor
may
earli
stage
presymptomat
infect
epidemiolog
model
gener
vcjd
patient
predict
protract
preclin
diseas
state
incub
time
may
exceed
year
individu
certain
genotyp
iatrogen
transmiss
prion
occur
patient
receiv
humanderiv
pituitari
hormon
human
growth
hormon
hgh
gonadotropin
cjd
transmit
recipi
cadaver
pituitari
hgh
prior
withdraw
countri
similarli
cadaver
pituitaryderiv
gonadotropin
use
treat
infertil
women
prior
associ
iatrogen
transmiss
cjd
cadaver
pituitari
hgh
sinc
replac
microbiallyproduc
recombin
gh
recombin
gonadotropin
cho
express
rhfsh
use
sinc
vcjd
caus
humanadapt
form
prion
respons
bse
unlik
prion
adapt
bse
prion
infect
multipl
speci
addit
human
suggest
possibl
addit
emerg
diseas
may
result
transmiss
prion
current
known
infect
human
one
transmiss
prion
diseas
chronic
wast
diseas
cwd
affect
elk
deer
potenti
pose
new
challeng
anim
human
health
remov
animalor
humanderiv
raw
materi
addit
biopharmaceut
manufactur
elimin
threat
infect
known
yet
unknown
prion
discoveri
new
infecti
agent
human
safeti
blood
suppli
reassess
often
result
expand
donor
deferr
screen
recommend
increas
exclus
donor
threaten
adequaci
blood
suppli
deriv
increas
risk
shortag
impact
avail
serum
plasmaor
serumdepend
product
addit
compound
issu
sera
use
manufactur
biopharmaceut
undefin
mixtur
individu
donor
sera
therefor
vari
composit
one
lot
next
consequ
product
extract
differ
pool
sera
also
heterogen
variabl
impos
requir
addit
qualiti
assur
step
manufactur
process
neg
impact
product
oper
cost
sinc
manufactur
recombin
plasmafre
product
requir
plasmaderiv
ingredi
pf
technolog
resolv
safeti
issu
also
enabl
manufactur
deliv
larg
quantiti
protein
independ
global
plasma
suppli
concern
safeti
process
consist
product
perform
regulatori
complianc
reliabl
suppli
prompt
mani
biolog
manufactur
progress
use
serum
use
serumfre
cell
cultur
media
next
step
progress
use
animalfre
media
ultim
switch
made
proteinfre
complet
synthet
chemic
defin
media
develop
serumfre
media
gener
difficult
must
individu
tailor
process
cell
line
fact
even
differ
clone
given
cell
line
like
cho
cell
may
requir
differ
formul
optim
growth
addit
shift
away
serum
often
come
tradeoff
reduc
yield
variou
supplement
current
use
mimic
effect
serum
promot
cell
viabil
optim
product
includ
protein
hydrolys
deriv
yeast
soy
wheat
hydrolys
contain
amino
acid
peptid
carbohydr
vitamin
essenti
element
ultrafiltr
remov
endotoxin
residu
protein
contamin
ensur
consist
averag
molecular
weight
three
relev
compon
serum
albumin
insulin
transferrin
tradit
bovin
serum
albumin
bsa
ad
serumfre
medium
lipid
transport
system
sourc
intermediari
metabolit
protect
agent
shear
forc
oxid
recombin
animalfre
human
albumin
commerci
avail
cell
cultur
recombin
human
insulin
produc
e
coli
yeast
e
coli
express
recombin
human
insulinlik
growth
factor
similarli
yeastderiv
animalfre
recombin
human
transferrin
market
supplement
among
grow
list
animalfre
reagent
supplement
enzym
commerci
support
plasmafre
mammalian
cell
cultur
advanc
made
gener
cell
line
less
depend
seraderiv
compon
exampl
includ
cho
cell
engin
produc
transferrin
andor
insulinlik
growth
factori
cho
cell
coexpress
von
willebrand
factor
vwf
along
fviii
vwf
serv
carrier
fviii
plasma
thought
stabil
effect
fviii
coexpress
vwf
fviii
lead
increas
accumul
fviii
activ
absenc
serum
growth
medium
beyond
product
phase
serumderiv
compon
tradit
use
address
challeng
associ
formul
protein
therapeut
recombin
therapeut
protein
requir
stabl
signific
shelf
life
good
bioavail
desir
characterist
present
challeng
product
formul
therapeut
protein
complex
tertiari
structur
often
time
larger
standard
small
molecul
drug
therefor
protein
often
sensit
wide
rang
factor
temperatur
ph
surfac
adsorpt
salt
concentr
typic
formul
mixtur
excipi
ensur
stabil
excipi
includ
sugar
polyol
amino
acid
polym
often
serum
albumin
case
final
materi
must
lyophil
avoid
loss
activ
storag
liquid
formul
frequent
necessari
prevent
protein
denatur
airliquid
interfac
nonion
deterg
polysorb
typic
use
purpos
addit
often
case
recombin
protein
requir
small
therapeut
dose
denatur
surfac
adsorpt
glass
vialsto
prevent
issu
bulk
agent
like
carbohydr
eg
sucros
protein
human
serum
albumin
hsa
animalderiv
gelatin
ad
excess
activ
protein
formul
excipi
hsa
excel
stabil
accept
safeti
profil
along
gelatin
tradit
among
commonli
use
excipi
howev
case
plasmaderiv
product
risk
pathogen
transmiss
could
elimin
addit
hsa
exhibit
structur
heterogen
batchtobatch
variabl
pharmacopoei
puriti
requir
undesir
compon
mixtur
polym
hsa
contamin
plasma
protein
remain
purif
process
concern
prompt
manufactur
switch
sugarbas
final
formul
develop
recombin
plasmafre
albumin
produc
saccharomyc
cerevisia
use
stabil
biopharmaceut
manufactur
similarli
pichia
pastori
yeast
engin
produc
recombin
animalfre
gelatin
present
reduc
risk
allerg
respons
compar
tissuederiv
substanc
pf
manufactur
requir
elimin
plasma
deriv
everi
step
process
fig
proper
postproduct
test
ensur
product
compromis
due
stress
proteinproduc
cell
lead
aberr
express
profil
individu
step
plasmafre
product
process
includ
develop
select
cell
line
transfect
cell
establish
viabl
cell
bank
yield
high
protein
output
serumfre
medium
sfm
well
retain
viabil
product
cryopreserv
serumfre
condit
requir
extens
process
wean
adapt
cell
ii
upstream
process
product
protein
stabl
animalfre
cell
cultur
medium
iii
downstream
process
purif
protein
without
addit
plasma
protein
iv
final
formul
formul
product
without
albumin
animalderiv
addit
v
test
rigor
test
assur
safeti
efficaci
pf
product
preand
postmarket
set
ensur
conformationintegr
molecul
compromis
recombin
human
protein
shown
immunogen
although
antibodi
respons
gener
gener
variabl
low
titer
howev
antibodi
inhibit
drug
efficaci
caus
lifethreaten
complic
direct
either
endogen
selfprotein
exogen
therapeut
protein
product
antibodi
recombin
protein
influenc
sever
factor
includ
structur
properti
protein
formul
dose
rout
administr
presenc
impur
format
aggreg
exampl
high
molecular
weight
complex
form
hsa
link
format
neutral
antibodi
interferon
molecul
prompt
research
develop
albuminfre
formul
hsa
replac
excipi
prevent
oxid
adsorpt
aggregationa
new
formul
rnf
rebif
new
formul
emd
serono
approv
europ
august
treatment
relaps
form
multipl
sclerosi
rnf
hsafre
produc
cho
cell
line
serumfre
cultur
medium
overal
result
phase
iiib
studi
suggest
rnf
improv
local
toler
immunogen
compar
histor
studi
origin
formul
author
attribut
benefit
larg
absenc
serum
compon
hsa
fb
prepar
optim
clinic
outcom
follow
treatment
biopharmaceut
issu
special
relev
immunecompromis
patient
struggl
chronic
diseas
repeat
infus
extend
period
lifetim
patient
increas
cumul
risk
pathogen
transmiss
therapeut
monoclon
antibodi
mab
present
innov
approach
treatment
ill
immun
system
may
compromis
cancer
autoimmun
diseas
inflammatori
disord
success
wave
technolog
advanc
mab
develop
murin
antibodi
chimer
human
antibodi
final
fullyhuman
antibodi
mab
manufactur
trend
toward
adapt
cell
line
serumfre
media
along
remov
anim
compon
purif
formul
process
one
first
exampl
trend
tumor
necrosi
factor
alpha
antagonist
approv
treatment
sever
autoimmun
diseas
includ
rheumatoid
arthriti
inflammatori
bowel
diseas
tnf
antagonist
evolv
chimer
mab
produc
cell
grown
media
conta
serum
compon
remicad
centocor
fulli
human
mab
plasmafre
manufactur
formul
humira
abbott
sinc
tnf
play
critic
role
modul
inflammatori
immun
respons
patient
treat
tnf
antagonist
special
risk
seriou
infect
emphas
need
therapi
complet
pathogenfre
prevent
therapi
vaccin
minim
risk
pathogen
transmiss
also
paramount
import
sinc
vaccin
typic
administ
larg
number
children
elderli
individualsanim
proteinfre
technolog
appli
develop
pandem
season
influenza
vaccin
embryon
eggbas
technolog
current
replac
mammalian
cell
line
grown
serumfre
proteinfre
medium
exampl
includ
vero
cellbas
pandem
mockup
vaccin
complet
preclin
develop
await
licensur
baxter
new
mdck
cellbas
season
influenza
vaccin
recent
licens
europ
optaflu
novarti
aftermath
vcjd
outbreak
uk
recognit
prion
transmit
blood
access
potenti
infect
patient
dental
surgic
care
impact
uk
govern
requir
quarantin
equip
procedur
room
use
patient
risk
contract
vcjd
infect
donor
includ
hemophilia
patient
receiv
plasmaderiv
factor
concentr
prohibit
logist
cost
dedic
equip
atrisk
patient
may
made
hospit
dental
provid
less
like
offer
standard
servic
patient
problem
mitig
provid
previous
untreat
patient
product
manufactur
without
addit
animalderiv
compon
product
obviou
choic
young
previouslyuntr
unexpos
patient
also
consid
patient
exist
infect
hiv
hbv
hcv
must
concern
introduct
addit
pathogen
could
complic
preexist
infect
anoth
import
factor
consid
fear
exposur
potenti
pathogen
serumcontain
therapeut
may
caus
patient
forgo
prescrib
treatment
avail
product
risk
pathogen
transmiss
may
improv
patient
complianc
lead
better
treatment
outcom
improv
qualiti
life
assur
safeti
recombin
therapeut
protein
primari
concern
regulatori
agenc
provid
organ
manufactur
altern
humanor
animalderiv
materi
exist
best
measur
avail
assur
product
safeti
control
sourc
raw
materi
test
raw
materi
possibl
contamin
infecti
agent
implement
variou
virusinactiv
remov
step
test
end
product
confirm
absenc
pathogen
follow
bse
outbreak
strict
requir
impos
manufactur
biolog
medic
devic
regard
countri
origin
bovinederiv
materi
use
manufactur
http
wwwfdagovcberbsebsehtm
drug
compani
forc
find
altern
list
countri
provision
free
mad
cow
diseas
dwindl
list
restrict
countri
updat
includ
countri
bse
known
exist
also
countri
case
bse
identifi
consid
us
depart
agricultur
less
restrict
import
requir
us
andor
independ
surveil
biolog
manufactur
cber
center
biolog
evalu
research
requir
manufactur
provid
detail
inform
cell
cultur
histori
isol
media
ident
pathogen
test
cell
line
use
product
biolog
product
addit
sourc
control
measur
includ
expand
human
donor
screen
deferr
guidelin
howev
safeti
regul
set
forth
govern
vari
countri
variat
compound
donor
screen
polici
may
differ
even
within
countri
note
us
center
diseas
control
prevent
cdc
previou
test
sourc
materi
inadequ
due
routin
failur
serolog
screen
detect
newli
infect
donor
preseroconvers
phase
infect
remain
singl
greatest
risk
transfusiontransmit
viral
infect
sensit
test
institut
pcrbase
nucleic
acid
amplif
test
nat
includ
minipool
nat
singl
donor
test
id
nat
hiv
hcv
nat
expect
shorten
lag
time
infect
detect
day
hiv
day
hcv
nat
abl
complet
elimin
lag
time
donat
blood
routin
test
pathogen
hbv
hcv
htlvi
ii
syphili
wnv
applic
nat
use
detect
hiv
hcv
wnv
new
pathogen
emerg
new
test
continu
develop
implement
test
trypanosoma
cruzi
agent
chaga
diseas
method
inactiv
remov
virus
blood
product
first
evolv
respons
hiv
epidem
hemophilia
patient
becam
standard
practic
method
includ
pasteur
vapor
heat
low
ph
solventdeterg
treatment
separationpurif
techniqu
ionexchang
immunoaffin
chromatographi
nanofiltrationthes
step
help
significantli
reduc
frequenc
infect
origin
blood
suppli
especi
pathogen
screen
also
perform
howev
risk
novel
emerg
pathogen
must
taken
serious
note
cdc
order
protect
safeti
blood
suppli
bloodderiv
therapi
must
recogn
new
pathogen
continu
emerg
uk
health
offici
withdrew
blood
blood
product
obtain
donor
vcjd
subsequ
detect
today
plasma
use
uk
produc
therapeut
import
uk
among
mani
countri
includ
australia
new
zealand
denmark
ireland
canada
japan
switch
recombin
product
standard
treatment
hemophilia
regulatori
agenc
physician
organ
north
america
europ
prompt
drug
devic
manufactur
find
altern
human
anim
raw
materi
addit
whenev
possibl
tabl
fda
intern
confer
harmonis
develop
guidelin
regulatori
bodi
european
union
japan
us
provid
document
guid
sourc
character
test
raw
materi
deriv
human
anim
well
guid
evalu
protein
therapeut
presenc
virus
object
avoid
transmiss
adventiti
agent
issu
would
exist
animalfre
substanc
use
manufactur
process
regulatori
concern
serum
animalderiv
compon
product
manufactur
differ
formul
depend
regulatori
requir
countri
distribut
aranesp
amgen
recombin
human
erythropoietin
modifi
contain
addit
nglycosyl
site
increas
serum
half
life
although
aranesp
avail
hsacontain
hsafre
formul
us
hsafre
formul
contain
polysorb
approv
use
europ
recombin
therapeut
protein
broadli
categor
blood
factor
anticoagul
growth
factor
cytokin
hormon
vaccin
therapeut
enzym
monoclon
antibodi
categori
evolut
occur
manufactur
engin
product
result
better
therapeut
outcom
enhanc
safeti
lower
immunogen
increas
halflif
improv
bioavail
altern
rout
administr
enhanc
human
blood
plasma
administ
infecti
diseas
due
transmiss
infect
agent
total
exclud
also
appli
pathogen
unknown
medic
scientif
advisori
council
encourag
manufactur
avoid
use
human
anim
nation
hemophilia
foundat
us
protein
manufactur
product
uk
haemophilia
centr
guidelin
choos
recombin
concentr
manufactur
doctor
organis
formul
least
addit
human
anim
associ
hemophilia
guidelin
elimin
anim
human
protein
clinic
director
canada
stabil
final
formul
nutrient
cell
cultur
part
process
consid
goal
term
qualiti
product
ment
posit
impact
patient
complianc
consequ
treatment
outcom
safeti
biopharmaceut
come
forefront
patient
health
care
provid
due
outbreak
emerg
pathogen
notabl
hiv
hcv
vcjd
wnv
sar
multipl
region
world
http
wwwwho
risk
pathogen
transmiss
use
humanor
animalderiv
raw
materi
manufactur
pharmaceut
major
driver
behind
develop
pf
technolog
bloodderiv
product
special
risk
harbor
infecti
agent
thu
present
import
exampl
shift
safe
altern
produc
pf
manufactur
technolog
patient
hemophilia
particularli
high
risk
infect
bloodborn
pathogen
reli
plasmaderiv
plasmacontain
clot
factor
therapi
excess
high
risk
first
evidenc
transmiss
approxim
half
hemophilia
popul
prior
avail
screen
assay
viru
number
measur
implement
recent
year
ensur
safeti
plasma
deriv
measur
includ
screen
blood
donor
rigor
test
plasma
pool
incorpor
viru
inactiv
remov
step
manufactur
process
ultim
develop
recombin
product
measur
greatli
reduc
threat
pathogen
transmiss
risk
remain
number
recombin
product
still
incorpor
plasmaderiv
addit
manufactur
although
test
avail
screen
known
pathogen
test
exist
screen
blood
suppli
infecti
agent
prion
prion
parvoviru
may
marker
yet
undiscov
unrecogn
bloodborn
infecti
agent
masac
risk
unknown
pathogen
neglect
agent
may
appear
blood
suppli
futur
could
signific
impact
anyon
receiv
therapi
deriv
blood
produc
bloodderiv
addit
recombin
therapeut
protein
inject
mani
use
long
durat
treatment
chronic
diseas
case
repeat
infus
increas
cumul
risk
patient
complet
elimin
potenti
risk
transmiss
new
exist
infect
agent
recombin
therapeut
protein
produc
cell
line
absenc
humanor
animalderiv
protein
process
dedic
pathogen
remov
andor
inactiv
step
rigor
test
lipidand
nonlipidenvelop
virus
packag
stabil
absenc
humanor
animalderiv
protein
pf
process
often
serv
platform
develop
advanc
version
exist
drug
drug
genet
modifi
greater
efficaci
increas
halflif
lower
immunogen
other
tailor
effect
specif
group
patient
engin
effect
administ
less
invas
rout
erythropoeisisstimul
agent
introduc
late
manag
anemia
patient
chronic
kidney
diseas
serv
good
illustr
evolut
recombin
therapeut
protein
manufactur
first
recombin
product
replac
bloodderiv
predecessor
next
phase
product
longer
halflif
develop
darbepoetin
aranesp
product
evolv
convers
hsafre
formul
follow
serumfre
formul
epoetin
outsid
us
eprex
ortho
biotech
epoetin
neorecormon
roch
recent
pf
pegyl
recombin
erythropoietin
longer
halflif
develop
licens
europ
mircera
roch
advanc
optim
serumfre
media
product
mab
succeed
enhanc
hybridoma
product
product
qualiti
compar
tradit
cell
cultur
media
supplement
fb
nonetheless
elimin
animalderiv
compon
media
significantli
alter
cultur
perform
well
posttransl
protein
modif
glycosyl
pattern
antibodi
molecul
affect
structur
integr
thu
influenc
biolog
function
physicochem
properti
heterogen
glycosyl
pattern
evid
mab
produc
hybridoma
cell
grown
media
differ
serum
content
addit
influenc
pharmacokinet
glycosyl
may
influenc
efficaci
safeti
particularli
immunogen
factor
influenc
molecular
integr
protein
affect
immunogen
profil
physic
degrad
event
unfold
misfold
fragment
aggreg
biopharmaceut
may
becom
expos
variou
condit
stress
low
ph
heat
potenti
result
protein
misfold
format
amyloidlik
structur
mechan
differ
cultur
formul
storag
condit
affect
physic
stabil
protein
activ
area
biotechnol
j
wwwbiotechnologyjournalcom
research
biopharmaceut
requir
monitor
potenti
rare
safeti
issu
might
seen
studi
larg
number
patient
extend
period
time
thu
ensur
safeti
new
pf
product
phase
iv
postlicensur
safeti
surveil
studi
must
conduct
monitor
product
efficaci
well
rare
advers
event
review
factor
drive
develop
innov
solut
use
humanand
animalderiv
product
manufactur
biopharmaceut
question
remain
whether
regulatori
agenc
industri
gener
prepar
activ
embrac
chang
adopt
andor
mandat
use
pf
process
new
reformul
therapeut
protein
averag
cost
develop
biopharmaceut
product
exceed
billion
http
csdd
tuftsedu
manufactur
make
everi
effort
use
safest
possibl
technolog
pf
manufactur
process
given
major
infecti
agent
outbreak
occur
recent
year
fals
sens
secur
may
place
step
taken
avoid
complac
issu
need
address
pf
technolog
matur
becom
feasibl
accomplish
prior
next
major
threat
new
emerg
pathogen
